Research graph
References from In Silico and In Vitro development of novel small interfering RNAs (siRNAs) to inhibit SARS-CoV-2. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1080/17460441.2019.1581171
10.1080/17460441.2019.1581171 · External reference
10.1016/j.virol.2015.02.030
10.1016/j.virol.2015.02.030 · External reference
10.1056/nejmoa030747
10.1056/nejmoa030747 · External reference
10.1002/jmv.25685
10.1002/jmv.25685 · External reference
10.1016/j.virusres.2015.02.025
10.1016/j.virusres.2015.02.025 · External reference
Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment
10.1177/17534666221132736 · 2022 · External reference
Potential of siRNA in COVID-19 therapy: Emphasis on in silico design and nanoparticles based delivery
10.3389/fbioe.2023.1112755 · 2023 · External reference
10.1021/acscentsci.0c00272
10.1021/acscentsci.0c00272 · External reference
Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread
10.1093/nar/gkab1248 · 2022 · External reference
Inhibition of SARS-CoV-2 Replication by Self-Assembled siRNA Nanoparticles Targeting Multiple Highly Conserved Viral Sequences
2024 · External reference
A small interfering RNA (siRNA) database for SARS-CoV-2
10.1038/s41598-021-88310-8 · 2021 · External reference
10.1038/35078107
10.1038/35078107 · External reference
Engineering siRNA therapeutics: challenges and strategies
10.1186/s12951-023-02147-z · 2023 · External reference
10.1016/j.omtn.2023.06.010
10.1016/j.omtn.2023.06.010 · External reference
10.1016/j.jbi.2012.02.005
10.1016/j.jbi.2012.02.005 · External reference
Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference
10.1093/nar/gkh247 · 2004 · External reference
10.1016/j.bbrc.2004.02.157
10.1016/j.bbrc.2004.02.157 · External reference
10.1038/nbt936
10.1038/nbt936 · External reference
An in silico analysis of effective siRNAs against COVID-19 by targeting the leader sequence of SARS-CoV-2
10.1002/acg2.107 · 2021 · External reference
10.1016/j.meegid.2021.104951
10.1016/j.meegid.2021.104951 · External reference
10.1016/j.ygeno.2020.12.021
10.1016/j.ygeno.2020.12.021 · External reference
10.1038/nprot.2007.278
10.1038/nprot.2007.278 · External reference
MysiRNA-designer: a workflow for efficient siRNA design
10.1371/journal.pone.0025642 · 2011 · External reference
10.1093/molbev/mst010
10.1093/molbev/mst010 · External reference
10.1093/bioinformatics/btp033
10.1093/bioinformatics/btp033 · External reference
10.1093/nar/gkm699
10.1093/nar/gkm699 · External reference
10.1093/nar/gkn250
10.1093/nar/gkn250 · External reference
siVirus: web-based antiviral siRNA design software for highly divergent viral sequences
10.1093/nar/gkl214 · 2006 · External reference
Sfold web server for statistical folding and rational design of nucleic acids
10.1093/nar/gkh449 · 2004 · External reference
Comparison of approaches for rational siRNA design leading to a new efficient and transparent method
10.1093/nar/gkm088 · 2007 · External reference
siPRED: predicting siRNA efficacy using various characteristic methods
10.1371/journal.pone.0027602 · 2011 · External reference
10.1038/nbt1118
10.1038/nbt1118 · External reference
10.1093/nar/gkn188
10.1093/nar/gkn188 · External reference
Optimization of duplex stability and terminal asymmetry for shRNA design
10.1371/journal.pone.0010180 · 2010 · External reference
10.1093/nar/gkx279
10.1093/nar/gkx279 · External reference
10.1093/nar/gkl842
10.1093/nar/gkl842 · External reference
Akt2 kinase suppresses glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-mediated apoptosis in ovarian cancer cells via phosphorylating GAPDH at threonine 237 and decreasing its nuclear translocation
10.1074/jbc.m111.296905 · 2011 · External reference
Crystal Violet Assay for Determining Viability of Cultured Cells
10.1101/pdb.prot087379 · 2016 · External reference
10.1016/0022-1759(83)90303-4
10.1016/0022-1759(83)90303-4 · External reference
Unresolved reference
External reference
Multiple gene targeting siRNAs for down regulation of Immediate Early-2 (Ie2) and DNA polymerase genes mediated inhibition of novel rat Cytomegalovirus (strain All-03)
10.1186/s12985-020-01436-5 · 2020 · External reference
10.1016/j.jiph.2021.12.014
10.1016/j.jiph.2021.12.014 · External reference
10.1016/j.immuni.2020.03.007
10.1016/j.immuni.2020.03.007 · External reference
Geographic and Genomic Distribution of SARS-CoV-2 Mutations
10.3389/fmicb.2020.01800 · 2020 · External reference
10.3390/v12020244
10.3390/v12020244 · External reference
Genetic variation in SARS-CoV-2 may explain variable severity of COVID-19
10.1016/j.mehy.2020.109877 · 2020 · External reference
10.1038/s10038-020-0808-9
10.1038/s10038-020-0808-9 · External reference
10.1016/j.bbadis.2020.165878
10.1016/j.bbadis.2020.165878 · External reference
Role of ARID3A in E2F target gene expression and cell growth
10.5357/koubyou.80.1_15 · 2013 · External reference
RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription
10.1073/pnas.0437841100 · 2003 · External reference
10.1371/journal.pone.0159211
10.1371/journal.pone.0159211 · External reference
The design of optimal therapeutic small interfering RNA molecules targeting diverse strains of influenza A virus
10.1093/bioinformatics/btr555 · 2011 · External reference
10.1073/pnas.252758799
10.1073/pnas.252758799 · External reference
10.1038/sj.gt.3302479
10.1038/sj.gt.3302479 · External reference
10.1016/j.chom.2020.02.001
10.1016/j.chom.2020.02.001 · External reference
10.1038/sj.cr.7290286
10.1038/sj.cr.7290286 · External reference
Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract
2022 · External reference
Role of COVID-19 Vaccines in SARS-CoV-2 Variants
10.3389/fimmu.2022.898192 · 2022 · External reference
Development of primer-probe sets to rapidly distinguish single nucleotide polymorphisms in SARS-CoV-2 lineages
10.3389/fcimb.2023.1283328 · 2023 · External reference
10.1021/acs.molpharmaceut.0c01239
10.1021/acs.molpharmaceut.0c01239 · External reference
10.1038/s41586-020-2008-3
10.1038/s41586-020-2008-3 · External reference
Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2
10.1016/j.antiviral.2023.105677 · 2023 · External reference
10.1080/15476286.2023.2217400
10.1080/15476286.2023.2217400 · External reference
10.1038/nm1280
10.1038/nm1280 · External reference
10.1038/s41467-019-10280-3
10.1038/s41467-019-10280-3 · External reference
10.1074/jbc.rev120.013930
10.1074/jbc.rev120.013930 · External reference
10.1038/s41467-020-17495-9
10.1038/s41467-020-17495-9 · External reference
Structure and Function of Major SARS-CoV-2 and SARS-CoV Proteins
10.1177/11779322211025876 · 2021 · External reference
One Year of SARS-CoV-2: How Much Has the Virus Changed?
2021 · External reference
Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens
2020 · External reference
10.1093/clinchem/hvaa029
10.1093/clinchem/hvaa029 · External reference
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
10.2807/1560-7917.es.2020.25.3.2000045 · 2020 · External reference
10.1038/s41579-020-00468-6
10.1038/s41579-020-00468-6 · External reference
10.1111/febs.15815
10.1111/febs.15815 · External reference
Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection
10.1073/pnas.2219523120 · 2023 · External reference
A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant
10.15252/emmm.202115298 · 2022 · External reference
siRNA Specificity: RNAi Mechanisms and Strategies to Reduce Off-Target Effects
10.3389/fpls.2020.526455 · 2020 · External reference
Unresolved reference
External reference
10.1093/oxfordjournals.aje.a118408
10.1093/oxfordjournals.aje.a118408 · External reference
10.1016/j.imu.2021.100569
10.1016/j.imu.2021.100569 · External reference
Design of advanced siRNA therapeutics for the treatment of COVID-19
10.1016/j.mgene.2021.100910 · 2021 · External reference
Prediction of potential small interfering RNA molecules for silencing of the spike gene of SARS-CoV-2
10.4103/ijmr.ijmr_2855_20 · 2021 · External reference
Design of siRNA molecules for silencing of membrane glycoprotein, nucleocapsid phosphoprotein, and surface glycoprotein genes of SARS-CoV2
10.1186/s43141-022-00346-z · 2022 · External reference
Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2
10.3389/fbioe.2022.801870 · 2022 · External reference
10.1016/j.jksus.2022.102049
10.1016/j.jksus.2022.102049 · External reference
A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant
10.15252/emmm.202115298 · 2022 · External reference
